Phase II Trial of Combination Immunotherapy with Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High Risk HER2+ Breast Cancer Patients
ID Number 15-1088Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The goal of this clinical research study is to compare if and for how long trastuzumab combined with either NeuVax (nelipepimut-S given with GM-CSF [sargramostim]) or sargramostim can help to control the disease in patients with HER2 positive breast cancer.
Recruiting Patients: Yes